By Colin Kellaher

 

TG Therapeutics Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Briumvi for the treatment of relapsing forms of multiple sclerosis in adults.

The New York biopharmaceutical company said it expects a decision by the European Commission, which generally follows the CHMP's advice, in about two months.

The U.S. Food and Drug Administration in late December approved Briumvi for adults with relapsing forms of multiple sclerosis, a neurological disease that affects more than 2 million people around the world.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

March 31, 2023 07:59 ET (11:59 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.